Alcobra Ltd. (ADHD) Lowered to “Hold” at Cantor Fitzgerald
ADHD has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Alcobra from a sell rating to a hold rating in a research report on Tuesday, July 26th. Canaccord Genuity assumed coverage on shares of Alcobra in a report on Tuesday, June 7th. They issued a buy rating on the stock. Roth Capital reissued a buy rating and issued a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. WBB Securities lowered shares of Alcobra from a hold rating to a sell rating and cut their price target for the stock from $5.00 to $4.00 in a report on Monday, September 12th. Finally, Barclays PLC initiated coverage on shares of Alcobra in a report on Monday, August 1st. They issued an equal weight rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $8.34.
Shares of Alcobra (NASDAQ:ADHD) traded down 3.386% during mid-day trading on Thursday, hitting $2.425. 574,445 shares of the company traded hands. Alcobra has a 1-year low of $1.95 and a 1-year high of $8.78. The stock’s market capitalization is $66.84 million. The firm’s 50 day moving average price is $4.76 and its 200-day moving average price is $4.52.
Alcobra (NASDAQ:ADHD) last issued its earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. On average, equities research analysts forecast that Alcobra will post ($0.96) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in ADHD. Stifel Financial Corp increased its stake in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Jefferies Group LLC purchased a new stake in shares of Alcobra during the second quarter valued at $533,000. Palo Alto Investors LLC increased its stake in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock valued at $1,344,000 after buying an additional 36,218 shares in the last quarter. Finally, VHCP Management LLC increased its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares in the last quarter. 73.69% of the stock is currently owned by institutional investors.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.